Headquartered in Durham, NC Fiscal year ends December NASDAQ: BVS bioventus.com
Bioventus Inc. is a medical device company that develops and sells clinically supported, cost-effective products intended to help patients heal and return to active lives. Its portfolio is organized into three businesses.
- **Pain Treatments:** Hyaluronic acid (HA) viscosupplement injections such as Durolane for joint pain, a platelet-rich plasma (PRP) system, and peripheral nerve stimulation (PNS) products.
- **Surgical Solutions:** Ultrasonic surgical systems and disposables, and bone graft substitutes.
- **Restorative Therapies:** Mainly the EXOGEN non-invasive bone stimulation system for fracture healing.
The company sells mostly in the United States, which accounted for the large majority of quarterly net sales, with a growing international business. It operates through an Up-C structure: Class A shareholders own a stake in Bioventus LLC alongside noncontrolling interest holders.
Bioventus divested its Advanced Rehabilitation Business at the end of 2024. It operates under a 2025 Credit Agreement and has been paying down term debt. The company is currently reviewing potential strategic alternatives following an unsolicited acquisition proposal and other expressions of interest received in Q2 2026. Updated
Management trimmed full-year net sales guidance to $590 million to $595 million even as EPS beat for a sixth straight quarter, with revenue missing expectations. The review of strategic alternatives, triggered by an unsolicited acquisition proposal, stays open.
Consumer confidence is breaking down in a way investors have not seen in years. The University of Michigan Consumer Sentiment Index landed at 53.3 in March 2026, sitting below the 60 recessionary…
Bioventus Inc. is a medical device company that develops and sells clinically supported, cost-effective products intended to help patients heal and return to active lives.
The Wall Street consensus 12-month price target for BVS is $17.60.
